Active Filter(s):
Details:
Under the agreement, Alimera and Horus have agreed to increase the commercialization efforts for ILUVIEN (fluocinolone acetonide) for both diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in Europe.
Lead Product(s): Fluocinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Iluvien
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Alimera Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 03, 2023